Indeed, several small molecular drug design studies formulated molecules that can competitively target the Mdm2 p53-binding domain disrupting the formation of Mdm2-p53 complexes and, thus, reactivate p53 levels in cancer cells to promote p53-dependent cell death [16]. The gene discussed is MDM2; the disease is cancer.